<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02838381</url>
  </required_header>
  <id_info>
    <org_study_id>P/2011/117</org_study_id>
    <nct_id>NCT02838381</nct_id>
  </id_info>
  <brief_title>Study of Genetic and Cellular Immunological Parameters Predictive of Disease-free Survival in Patients With Metastatic Cancer</brief_title>
  <acronym>Epitopes-CRC01</acronym>
  <official_title>Study of Genetic and Cellular Immunological Parameters Predictive of Disease-free Survival in Patients With Metastatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to characterize the genetic and cellular immunological parameters of
      metastatic digestive cancer patients having short and long responses to chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>frequency of peripheral T cell immune responses in the presence of antigenic peptides associated with digestive cancer</measure>
    <time_frame>at inclusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>within 5 years after the inclusion</time_frame>
    <description>time interval between the date of inclusion and the date of first progression or death from any cause.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Metastatic Cancer</condition>
  <arm_group>
    <arm_group_label>Additional biological samples</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Additional blood samples will be realized at the inclusion of patients. Two optional blood samples could be realized if necessary with at least 3 months apart.
Peripheral Blood Mononuclear Cells (PBMC) will be collected. Tissue tumor will be collected if available.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Additional biological samples</intervention_name>
    <description>blood and tissue samples</description>
    <arm_group_label>Additional biological samples</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        For all patients:

          -  signed written informed consent

        For cohort A:

          -  patient with metastatic colorectal cancer with first-line therapy by chemotherapy +/-
             surgery and with a disease-free survival &gt; or = at 20 months

          -  Ct-scan realized in the previous 4 weeks and showing no progression according to the
             Recist criteria v1.1

        For cohort B:

          -  patient treated for metastatic colorectal cancer and chemotherapy responder (obtention
             of an objective response according to the Recist criteria V1.1 in first-line therapy),
             with a disease-free survival &lt; 10 months (disease progression must be confirmed by CT
             scan evaluation according to Recist v1.1 criteria)

        For cohort C:

          -  patients with no metastatic rectum cancer in complete remission after chemotherapy
             and/or radiotherapy

        For cohort D:

          -  patients with metastatic or locally advanced cancer in complete remission after
             treatment, non eligible in the other cohorts

        Exclusion Criteria:

        For all patients:

          -  patient with any medical or psychiatric condition or disease which would make the
             patient inappropriate for entry into this study

          -  patient with a neurodegenerative disease

          -  patient under guardianship, curator or under the protection of justice
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christophe Borg, Pr</last_name>
    <email>christophe.borg@efs.sante.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marine Jary, Dr</last_name>
    <email>mjary@chu-besancon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Besançon</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christophe BORG, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Nord Franche Comté</name>
      <address>
        <city>Montbéliard</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christophe BORG, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2016</study_first_submitted>
  <study_first_submitted_qc>July 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2016</study_first_posted>
  <last_update_submitted>July 20, 2016</last_update_submitted>
  <last_update_submitted_qc>July 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

